Initial preliminary efficacy and safety data are expected sometime next year, stated Aditya Bardia, MBBS, MPH, breast medical oncologist, Massachusetts General Hospital, Harvard Medical School.
Initial preliminary efficacy and safety data are expected sometime next year, followed by dose expansion and a phase 2 trial, explained Aditya Bardia, MBBS, MPH, breast medical oncologist, Massachusetts General Hospital, Harvard Medical School.
Transcript
What is the timeline for the phase 1B portion of the ASCENT trial investigating sacituzumab govitecan (SG) and talazoparib?
It is still ongoing. And we hope to have at least preliminary efficacy and safety tolerability data early next year, and then after that, the trial would expand to dose expansion as well as a phase 2 trial to further confirm the efficacy and safety tolerability. But in terms of initial preliminary data, sometime next year we should have those results.
Is there a timeline for the phase 1B portion?
In part that would depend on the efficacy of the data, how robust the results look, and that would help guide for the development of phase 2 or even phase 3.
Have additional patient safety measures been implemented with flu season and the coronavirus disease 2019 (COVID-19) pandemic overlapping?
Oh, it started absolutely in March of 2020 when Boston got hit with COVID-19. The institutions in the Boston region, including MGH, implemented a number of procedures to ensure that patients with cancer are safe, and those measures remain in place. We've not seen nosocomial or hospitals spread of COVID-19. And despite the pandemic, the clinical trial with SG plus [a] PARP inhibitor continued to enroll, and we had patients enrolled even when the pandemic was at its peak.
In Boston, we’ve not seen any COVID infection in patients who were treated with this agent, in part because of the preventive measures that have been instituted at our institution. One thing to consider is that neither SG nor [a] PARP inhibitor necessarily would increase the risk of either flu or COVID. But we know that triple-negative breast cancer is an aggressive disease, so it’s important to control the disease while ensuring that we take whatever precautions are needed.
We actually wrote a report about this as a CPC, or clinical pathological conference, in the New England Journal of Medicine that was published in July, talking about a patient with breast cancer during the COVID pandemic and how it could have an impact. And the bottom line was, we have to weigh the risks and benefits and take whatever precautions are needed, but at the same time, ensure that the anticancer treatment or the care of patient with breast cancer is not compromised.
Frameworks for Advancing Health Equity: Urban Health Outreach
May 9th 2024In the series debut episode of "Frameworks for Advancing Health Equity," Mary Sligh, CRNP, and Chelsea Chappars, of Allegheny Health Network, explain how the Urban Health Outreach program aims to improve health equity for individuals experiencing homelessness.
Listen
Tackling Health Inequality: The Power of Education and Experience
April 30th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our final episode of this limited series and our conversation with Janine Jelks-Seale, MSPPM, director of health equity at UPMC Health Plan.
Listen
Study Highlights Significant Increases in Utilization, Spending on DMD Drugs in Medicaid
May 17th 2024The findings add to recent research on the growing utilization, expenditure, and prices of Duchenne muscular dystrophy (DMD) therapies in the current landscape, an area health care policy could potentially address.
Read More